Effect of Adjuvant Chemotherapy on Survival Among Patients with Stage IIA Colorectal Cancer Following Radical Surgery: A Propensity Score-Matching Study Using the SEER Database.
Qilong Lan, Lanlan Xie, Dongbo Xu, Shuangming Lin, Changyu Li
{"title":"Effect of Adjuvant Chemotherapy on Survival Among Patients with Stage IIA Colorectal Cancer Following Radical Surgery: A Propensity Score-Matching Study Using the SEER Database.","authors":"Qilong Lan, Lanlan Xie, Dongbo Xu, Shuangming Lin, Changyu Li","doi":"10.1080/07357907.2025.2593470","DOIUrl":null,"url":null,"abstract":"<p><p>To explore the effect of adjuvant chemotherapy on the overall survival (OS) and cancer cause-specific survival (CSS) in patients with AJCC stage IIA colorectal cancer. Date of patients with stage IIA colorectal cancer who underwent radical surgery without radical therapy or preoperative chemotherapy were retrieved from the Surveillance, Epidemiology, and End Results database. Propensity score matching (1:1) was performed, yielding a cohort of 14819 patients. The 3-, 5- and 7- year OS rates in the non-chemotherapy group were 80.5%, 50.0% and 16.3%, respectively, compared with 97.2%, 86.0% and 57.3% in the chemotherapy group. Regardless of the risk factors, adjuvant chemotherapy significant improved the OS (<i>p</i> = 0.000), but not for CSS. The Cox proportional-hazards model revealed that age ≥ 65 years, male sex, unmarried status, rectal carcinoma, positive carcinoembryonic antigen, perineural invasion positive, fewer than 12 lymph nodes and multiple cancers were risk factors for both OS and CSS. However, adjuvant chemotherapy was a risk factor only for OS. Regardless of these risk factors or the presence of multiple cancers, adjuvant chemotherapy markedly improved OS in patients with stage IIA colorectal cancer, particularly in those with grade III/IV tumors or fewer than 12 lymph nodes, but has not been proven on CSS.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"39-50"},"PeriodicalIF":2.2000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2593470","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
To explore the effect of adjuvant chemotherapy on the overall survival (OS) and cancer cause-specific survival (CSS) in patients with AJCC stage IIA colorectal cancer. Date of patients with stage IIA colorectal cancer who underwent radical surgery without radical therapy or preoperative chemotherapy were retrieved from the Surveillance, Epidemiology, and End Results database. Propensity score matching (1:1) was performed, yielding a cohort of 14819 patients. The 3-, 5- and 7- year OS rates in the non-chemotherapy group were 80.5%, 50.0% and 16.3%, respectively, compared with 97.2%, 86.0% and 57.3% in the chemotherapy group. Regardless of the risk factors, adjuvant chemotherapy significant improved the OS (p = 0.000), but not for CSS. The Cox proportional-hazards model revealed that age ≥ 65 years, male sex, unmarried status, rectal carcinoma, positive carcinoembryonic antigen, perineural invasion positive, fewer than 12 lymph nodes and multiple cancers were risk factors for both OS and CSS. However, adjuvant chemotherapy was a risk factor only for OS. Regardless of these risk factors or the presence of multiple cancers, adjuvant chemotherapy markedly improved OS in patients with stage IIA colorectal cancer, particularly in those with grade III/IV tumors or fewer than 12 lymph nodes, but has not been proven on CSS.
期刊介绍:
Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.